Literature DB >> 11527796

Human lymphocyte proliferation responses following primary immunization with rabies vaccine as neoantigen.

G Ghaffari1, D J Passalacqua, B S Bender, D J Briggs, M M Goodenow, J W Sleasman.   

Abstract

Evaluation of the T-cell immune response following primary antigenic challenge with a neoantigen is a critical aspect of assessment of the cellular immune response. While many antigens can be used to accurately assess in vitro T-cell proliferation to a recall antigen, only a few neoantigens have been tested for their capacities to measure T-cell responses in vitro to a primary immunization. Rabies vaccination is an excellent candidate for the testing of T-cell proliferation responses to a primary immunization because few individuals have been exposed to rabies virus antigens. In the present study 14 rabies vaccine-naïve, healthy adult volunteers were immunized against rabies virus, and T-cell proliferation and antibody responses were measured before and after vaccination. Optimal lymphocyte proliferation to soluble rabies virus antigen occurred after 8 days in culture. The average level of uptake of tritiated thymidine postimmunization was 29,620 +/- 4,448 cpm, whereas preimmunization levels were 12,660 +/- 3,448 cpm (P = 0.002). All individuals showed increases in rabies virus antibody titers from <0.05 to 5.59 +/- 1.64 IU/ml. The degree of proliferation to tetanus toxoid as a recall antigen was similar to the response to rabies virus antigen among the cohort. Due to high levels of preimmunization proliferation, four subjects failed to demonstrate a twofold increase in response to rabies virus antigen. The high levels of T-cell responses may be due to a viral superantigen effect in some individuals. Rabies vaccination offers a safe and effective means for measurement of both T- and B-cell immune responses to a neoantigen in healthy and immune suppressed individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11527796      PMCID: PMC96164          DOI: 10.1128/CDLI.8.5.880-883.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  19 in total

1.  Rabies prevention--United States, 1991. Recommendations of the Immunization Practices Advisory Committee (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1991-03-22

2.  The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines.

Authors:  P S Wunderli; J H Shaddock; D S Schmid; T J Miller; G M Baer
Journal:  Vaccine       Date:  1991-09       Impact factor: 3.641

3.  In vitro primary immunization of human peripheral blood lymphocytes to KLH: evidence for HLA-D-region restriction.

Authors:  G E Rodey; L K Luehrman; D W Thomas
Journal:  Transplant Proc       Date:  1979-12       Impact factor: 1.066

4.  Primary sensitisation and restimulation of human lymphocytes with soluble antigen in vitro.

Authors:  E J Hensen; B G Elferink
Journal:  Nature       Date:  1979-01-18       Impact factor: 49.962

5.  In vitro proliferative responses of human peripheral blood mononuclear cells to non-recall antigens.

Authors:  J L Young; A Daser; P C Beverley
Journal:  J Immunol Methods       Date:  1995-06-09       Impact factor: 2.303

6.  Lymphocyte proliferation assays may underestimate antigen responsiveness in human immunodeficiency virus infection.

Authors:  A H Patki; S F Purvis; H J Meyerson; M M Lederman
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

7.  Evidence for a viral superantigen in humans.

Authors:  M Lafon; M Lafage; A Martinez-Arends; R Ramirez; F Vuillier; D Charron; V Lotteau; D Scott-Algara
Journal:  Nature       Date:  1992-08-06       Impact factor: 49.962

8.  Aging and the immune response to tetanus toxoid: diminished frequency and level of cellular immune reactivity to antigenic stimulation.

Authors:  D Schatz; T Ellis; E Ottendorfer; E Jodoin; D Barrett; M Atkinson
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

9.  Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study.

Authors:  D B Fishbein; K M Yenne; D W Dreesen; C F Teplis; N Mehta; D J Briggs
Journal:  Vaccine       Date:  1993-11       Impact factor: 3.641

10.  Dependency on interleukin-1 of primary human in vitro T cell responses to soluble antigens.

Authors:  M Plebanski; C J Elson; W D Billington
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

View more
  6 in total

1.  Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.

Authors:  Guity Ghaffari; Daniel L Tuttle; Daniel Briggs; Brant R Burkhardt; Deepa Bhatt; Warren A Andiman; John W Sleasman; Maureen M Goodenow
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Retrospective analysis of wound characteristics and tetanus development in captive macaques.

Authors:  Danielle A Springer; Kathrine Phillippi-Falkenstein; Gary Smith
Journal:  J Zoo Wildl Med       Date:  2009-03       Impact factor: 0.776

3.  Evaluation of copper toxicity in isolated human peripheral blood mononuclear cells and it's attenuation by zinc: ex vivo.

Authors:  Rashim Pal Singh; Sandeep Kumar; Ritambra Nada; Rajendra Prasad
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.842

Review 4.  The Cellular Immune Response to Rabies Vaccination: A Systematic Review.

Authors:  Lisanne A Overduin; Jacques J M van Dongen; Leonardus G Visser
Journal:  Vaccines (Basel)       Date:  2019-09-11

5.  Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man.

Authors:  D M C Brinkman; C M Jol-van der Zijde; M M ten Dam; J M Vossen; A D M E Osterhaus; F P Kroon; M J D van Tol
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.542

6.  HIV-1 activates macrophages independent of Toll-like receptors.

Authors:  Joseph N Brown; James J Kohler; Carter R Coberley; John W Sleasman; Maureen M Goodenow
Journal:  PLoS One       Date:  2008-12-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.